1223 related articles for article (PubMed ID: 30559740)
21. [Gene-modified T-cell therapy using chimeric antigen receptors for pediatric hematologic malignancies].
Nakazawa Y
Rinsho Ketsueki; 2016 Jun; 57(6):701-8. PubMed ID: 27384848
[TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
23. [Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies -Review].
Cheng X; Wang YJ; Feng S; Wu YY; Yang TH; Lai X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):626-630. PubMed ID: 29665944
[TBL] [Abstract][Full Text] [Related]
24. CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies.
Miller BC; Maus MV
Oncol Res Treat; 2015; 38(12):683-90. PubMed ID: 26633875
[TBL] [Abstract][Full Text] [Related]
25. Future directions in chimeric antigen receptor T cell therapy.
Maude SL
Curr Opin Pediatr; 2017 Feb; 29(1):27-33. PubMed ID: 27841776
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
27. Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.
Kiesgen S; Chicaybam L; Chintala NK; Adusumilli PS
J Thorac Oncol; 2018 Jan; 13(1):16-26. PubMed ID: 29107016
[TBL] [Abstract][Full Text] [Related]
28. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
Geyer MB; Brentjens RJ
Cytotherapy; 2016 Nov; 18(11):1393-1409. PubMed ID: 27592405
[TBL] [Abstract][Full Text] [Related]
29. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
Lindo L; Wilkinson LH; Hay KA
Front Immunol; 2020; 11():618387. PubMed ID: 33643299
[TBL] [Abstract][Full Text] [Related]
30. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.
Feins S; Kong W; Williams EF; Milone MC; Fraietta JA
Am J Hematol; 2019 May; 94(S1):S3-S9. PubMed ID: 30680780
[TBL] [Abstract][Full Text] [Related]
31. CAR-T cell therapy in melanoma: A future success story?
Simon B; Uslu U
Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
[TBL] [Abstract][Full Text] [Related]
32. INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults.
Talleur AC; Fabrizio VA; Aplenc R; Grupp SA; Mackall C; Majzner R; Nguyen R; Rouce R; Moskop A; McNerney KO
Transplant Cell Ther; 2024 Jun; 30(6):565-579. PubMed ID: 38588880
[TBL] [Abstract][Full Text] [Related]
33. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
34. [CAR T-cell therapy: Balance of efficacy and safety].
Kulemzin SV; Kuznetsova VV; Mamonkin M; Taranin AV; Gorchakov AA
Mol Biol (Mosk); 2017; 51(2):274-287. PubMed ID: 28537234
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
Li J; Li W; Huang K; Zhang Y; Kupfer G; Zhao Q
J Hematol Oncol; 2018 Feb; 11(1):22. PubMed ID: 29433552
[TBL] [Abstract][Full Text] [Related]
36. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
[TBL] [Abstract][Full Text] [Related]
37. What CAR Will Win the CD19 Race?
Quintás-Cardama A
Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581
[TBL] [Abstract][Full Text] [Related]
38. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
Bagley SJ; O'Rourke DM
Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
[TBL] [Abstract][Full Text] [Related]
39. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
40. Adoptive T-Cell Therapy for Solid Tumors.
Yeku O; Li X; Brentjens RJ
Am Soc Clin Oncol Educ Book; 2017; 37():193-204. PubMed ID: 28561728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
